17-dihydroexemestane and Breast-Neoplasms

Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good tolerability. Here, its pharmacological and biological aspects as well as its clinical applications and comparison to other endocrine therapeutic agents, are reviewed. It is also focused the benefits and risks of exemestane, drawbacks to be overcome and aspects to be explored.

Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles